NATICK, Mass., May 11, 2011 /PRNewswire/ — Boston Scientific
Corporation (NYSE:
BSX) today announced that a jury in the District Court for the
District of Delaware found that Cordis Corporation owed Boston
Scientific approximately $19.5 million for infringing its Jang
patent, which covers intellectual property associated with coronary
stent technologies. The jury awarded $18.5 million in lost
profits and $1 million in reasonable royalties to Boston
Scientific.
Boston Scientific brought suit against Cordis for patent
infringement in December 2009, shortly after the U.S. launch of
Cordis’ 2.25 mm Cypher® Stent. On April 13, 2011 the
Delaware Court ruled that, as a matter of law, Cordis infringed
Boston Scientific’s Jang patent and later found that Cordis’
infringement was willful.
“We are pleased to see the jury recognize the value of our
intellectual property,” said Hank Kucheman, Executive Vice
President and Group President, Cardiology, Rhythm and Vascular for
Boston Scientific. “This is an important outcome in
protecting our market position in small-vessel, drug-eluting stents
against infringing products.”
About Boston ScientificBoston Scientific is a worldwide
developer, manufacturer and marketer of medical devices whose
products are used in a broad range of interventional medical
specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like “anticipate,” “expect,”
“project,” “believe,” “plan,” “estimate,” “intend” and similar
words. These forward
‘/>”/>
